GlassScriptPhysician profile
Tomas Valdez
NPI 1811092687
$2,953.42
in general payments reported to CMS, 2019-2025
36 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $687 · 2021: $704 · 2022: $380 · 2023: $261 · 2024: $150 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $558.71 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $453.07 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $235.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $186.85 | 2019-2023 | Verquvo, Belsomra, Januvia |
| Ani Pharmaceuticals, INC. | $132.34 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $121.37 | 2019-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $120.40 | 2020-2021 | |
| Philips North America LLC | $70.67 | 2025 | Mcot, Vest Therapy Und |
| Chiesi USA, INC. | $66.52 | 2019-2020 | |
| Organogenesis INC. | $65.50 | 2020-2021 | |
| Amgen INC. | $61.66 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $59.30 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $53.49 | 2021-2025 | Austedo Xr |
| Stryker Corporation | $50.78 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.25 | 2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $45.69 | 2022 | |
| Glaxosmithkline, LLC. | $44.22 | 2019-2020 | |
| Lilly USA, LLC | $43.58 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $43.37 | 2021 | |
| Biogen, INC. | $43.21 | 2021 | |
| Scilex Pharmaceuticals INC. | $42.95 | 2020-2021 | |
| Abbott Laboratories | $42.75 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.43 | 2022-2023 | Jardiance |
| Hikma Pharmaceuticals USA | $36.16 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $34.48 | 2025 | |
| Neurocrine Biosciences, INC. | $33.38 | 2024 | Ingrezza |
| Horizon Therapeutics Plc | $32.25 | 2019 | |
| Agepha Pharma Fz LLC | $27.92 | 2025 | Lodoco |
| Melinta Therapeutics, LLC | $27.02 | 2019 | |
| Orthofix Medical, INC. | $25.58 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.07 | 2022 | |
| Forte Bio-Pharma LLC | $21.09 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.37 | 2019 | |
| Smith+Nephew, INC. | $14.92 | 2021 | |
| Nabriva Therapeutics, Plc | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Valdez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.